• Latest Posts

A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy

In Depth 19 Jun 2023

Gene therapy: a promising solution for sickle cell disease

Milestone for gene-edited therapy for sickle cell disease

In Depth 20 Oct 2022

Opportunities and challenges for cell and gene therapy investments

The Billion-Euro European Biotech Companies in 2022


Gene-Edited T Cell Therapy Players Battle Safety Doubts

Interview 3 Mar 2021

The Promises of CRISPR Genome Editing in Biomedicine

The 21 European Biotech Companies To Watch in 2021

Covid-19 Leaves Lasting Impact on Hematology at ASH 2020 Conference

CRISPR Cell Therapy Shows Early Promise for Treating Blood Disorders